Actively Recruiting

Phase Not Applicable
Age: 18Years - 65Years
All Genders
NCT04859335

Evolution of Balance and Vestibular Function in Patients Treated With Gammaknife Radiosurgery for Vestibular Schwannoma

Led by University Hospital, Toulouse · Updated on 2024-08-02

50

Participants Needed

1

Research Sites

393 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Vestibular schwannomas are benign lesions of the ponto-cerebellar angle that are potentially dangerous because of their growth in a cramped space and the compressive phenomena they can cause. Stereotactic Gammaknife radiosurgery is a treatment option that can be offered for evolutive schwannomas smaller than 2.5-3 cm in size. It allows tumor stabilisation in 85% of cases with less than 1% facial nerve damage risk. There are controversial results regarding hearing preservation : percentages vary between 25 and 80% in the literature, depending on the criteria used and the post-treatment delay. Few studies have investigated changes in vestibular function and the impact on balance of radiosurgery, and their results are variable. These controversial results lead us to comprehensively assess the vestibular function and balance of these patients using a balance-specific quality of life questionnaire, in addition to objective overall vestibular assessments of vestibular function.

CONDITIONS

Official Title

Evolution of Balance and Vestibular Function in Patients Treated With Gammaknife Radiosurgery for Vestibular Schwannoma

Who Can Participate

Age: 18Years - 65Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Patients diagnosed with vestibular schwannoma recommended for Gammaknife radiosurgery by a multidisciplinary team
  • No previous treatment for the vestibular schwannoma
  • Affiliated with Social Security
  • No opposition to participation
Not Eligible

You will not qualify if you...

  • Previous treatment for vestibular schwannoma, including surgery or fractional radiotherapy
  • History of other ear or nerve-related disorders linked to the schwannoma
  • Diagnosis of type 2 neurofibromatosis
  • Under legal protection
  • Pregnant or breastfeeding women

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

CHU Toulouse

Toulouse, France

Actively Recruiting

Loading map...

Research Team

M

Mathieu MARX, MD Phd

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

HEALTH_SERVICES_RESEARCH

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here